Sweeping TAVR changes on the way | Pushing back against AI-powered prior authorization | FDA highlights recall after injuries

Major TAVR policy changes appear to be on the way—should clinicians be excited or concerned? Leading U.S. medical societies are sharing their early reactions.

ASE, ASNC and SCAI have come out against a WiSER model using AI for traditional Medicare prior authorizations.

This latest recall was put in place due to an increased risk of blood clots developing during use. Only a small number of hospitals are affected. 

A recent OIG report suggested vascular surgeons, interventional cardiologists and interventional radiologists may be performing medically unnecessary procedures in office-based labs. Now, some of the leading medical societies from those fields have provided additional context. 

The issue at the heart of this recall has been linked to three patient deaths. 

The ankle-brachial index, a noninvasive diagnostic test for peripheral artery disease, may provide even more value than clinicians previously realized. 

A failed TAVR procedure has left one family unsure about where things went wrong. 

One of the project's biggest goals is helping clinicians identify patients in need of care earlier than ever.